<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904823</url>
  </required_header>
  <id_info>
    <org_study_id>FMTN-II-203-NSCLC</org_study_id>
    <nct_id>NCT03904823</nct_id>
  </id_info>
  <brief_title>A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC</brief_title>
  <official_title>An Open, Single-arm, Multi-center, Phase 2 Clinical Trial of Famitinib Combined With Epidermal Growth Factor Receptor (EGFR) Inhibitor HS-10296 in Patients With Advanced EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib
      combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depth of Response (DepOR)</measure>
    <time_frame>From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Percentage of total target lesion diameter reduced from baseline when at best overall response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first partial response or complete response until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From the start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Ratio (CBR)</measure>
    <time_frame>From the start of treatment to 6 months</time_frame>
    <description>Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month-PFS</measure>
    <time_frame>From the start of treatment to 12 months</time_frame>
    <description>12-month-progression free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free-Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically significant toxicity</measure>
    <time_frame>First cycle (21 days)</time_frame>
    <description>Number of Participants with Clinically significant toxicity per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events and Serious Adverse Events</measure>
    <time_frame>From the first drug administration to within 30 days after the last dose</time_frame>
    <description>Rate of Adverse Events and Serious Adverse Events per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>EGFR-mutant Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>famitinib, HS-10296</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famitinib po</intervention_name>
    <description>Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.</description>
    <arm_group_label>famitinib, HS-10296</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-10296 po</intervention_name>
    <description>Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.</description>
    <arm_group_label>famitinib, HS-10296</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's written informed consent obtained prior to any process, sampling, or
             analysis related to the study.

          -  Male or female, no less than 18 years old.

          -  Confirmed as NSCLC by histology or cytology.

          -  Locally advanced or metastatic NSCLC and not suitable for radical surgery or
             radiotherapy.

          -  Have not received EGFR Tyrosine Kinase Inhibitor (TKI) therapy.

          -  At least one baseline tumor lesion.

          -  Can swallow pills normally.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0~1 points, expected
             survivalâ‰¥12 weeks.

          -  Adequate organ function.

        Exclusion Criteria:

          -  Clinically symptomatic central nervous system metastases.

          -  Ascites, pleural effusion or pericardial effusion with clinical symptoms.

          -  Other malignant tumors in the past 5 years or at the same time.

          -  High blood pressure which are not well controlled.

          -  Heart disease that are not well controlled.

          -  Coagulation dysfunction, bleeding tendency or receiving thrombolysis or anticoagulant
             therapy.

          -  History of bleeding.

          -  Known hereditary or acquired bleeding and thrombophilia.

          -  Any serious or uncontrolled ocular lesion.

          -  Interstitial lung disease or non-infectious pneumonia treated with corticosteroids.

          -  Congenital or acquired immunodeficiency.

          -  Other factors that may affect the results of the study or cause the study to be
             terminated midway.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caicun Zhou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quanren Wang, Doctor</last_name>
    <phone>+86 18036618570</phone>
    <email>wangquanren@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weixia Li, Master</last_name>
    <phone>+86 15005136260</phone>
    <email>liweixia@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

